A randomized phase 3 trial evaluating antithrombin gamma treatment in Japanese patients with early-onset severe preeclampsia (KOUNO-TORI study): Study protocol
Shigeru Saito(Shonan Kamakura General Hospital), Hiroyuki Seki(Social Insurance Saitama Chuo Hospital), Tomoko Adachi(Kisarazu Hospital), Hiroshi Sameshima, Takao Kobayashi(Hokkaido University), Hisashi Masuyama(Okayama University), Akihide Ohkuchi(Jichi Medical University), Junji Moriya(New Tokyo Hospital), Naohiro Kanayama(Hamamatsu Medical Center), Mamoru Morikawa(Hokuyukai Neurology Hospital), Ken-ichi Takagi(Kyowa Kirin (Japan)), Satoru Takeda(Social Insurance Saitama Chuo Hospital), Haruhiko Sago(National Center For Child Health and Development)
Cited by 7
Related Papers
Rationale and study design of the Japan environment and children’s study (JECS)
|BMC Public Health|2014|852
IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs
|The Journal of Immunology|2011|552
The Danger Signal, Extracellular ATP, Is a Sensor for an Airborne Allergen and Triggers IL-33 Release and Innate Th2-Type Responses
|The Journal of Immunology|2011|490
IL-33–activated dendritic cells induce an atypical TH2-type response
|Journal of Allergy and Clinical Immunology|2009|400
Randomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia
|New England Journal of Medicine|2021|384